What is the Descartes-08 Clinical Trial?
This Phase I/II clinical trial of its lead CAR-T product, Descartes-08, is evaluating the safety and feasibility of the therapy in eligible patients with generalized myasthenia gravis (GMG).
Am I eligible?
You may be eligible if are 18 years and older and have:
- Generalized myasthenia gravis
- Failed treatment over 1 year or more with 2 or more immunosuppressive therapies (ISTs)
- Have no major chronic illness that is not well managed at the time of study entry
Additional eligibility criteria are available on ClinicalTrials.gov.
What Will Happen?
If you choose to participate and qualify, Descartes-08 will be custom-made for you from your own blood cells. Descartes-08 cells are CAR T-cells, which are T-cells that have been modified to eliminate plasma cells that produce disease-causing autoantibodies. To modify the cells, the Sponsor inserts new instructions into the T-cells. These instructions cause the cells to produce a new piece of cellular machinery called a CAR (Chimeric Antigen Receptor).
How will I receive Descartes-08?
Descartes-08 will be infused into your bloodstream.
Will I be reimbursed for travel and accommodation?
Reimbursement may be provided for some types of travel and accommodation. Please contact study staff for details.
University of Miami
University of California – Irvine